196 related articles for article (PubMed ID: 32938641)
41. Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1.
Liu L; Ruiz J; O'Neill SS; Grant SC; Petty WJ; Yang M; Chen K; Topaloglu U; Pasche B; Zhang W
Mol Cancer; 2018 Apr; 17(1):81. PubMed ID: 29650000
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
Song Z; Cheng G; Xu C; Wang W; Shao Y; Zhang Y
Lung Cancer; 2018 Apr; 118():57-61. PubMed ID: 29572003
[TBL] [Abstract][Full Text] [Related]
43. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.
Church DN; Briggs SE; Palles C; Domingo E; Kearsey SJ; Grimes JM; Gorman M; Martin L; Howarth KM; Hodgson SV; ; Kaur K; Taylor J; Tomlinson IP
Hum Mol Genet; 2013 Jul; 22(14):2820-8. PubMed ID: 23528559
[TBL] [Abstract][Full Text] [Related]
44. PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation.
Schenck K; Masetti M; Pfarr N; Lorenzen S
Oncol Res Treat; 2022; 45(4):222-226. PubMed ID: 34875656
[TBL] [Abstract][Full Text] [Related]
45. Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.
Yao J; Gong Y; Zhao W; Han Z; Guo S; Liu H; Peng X; Xiao W; Li Y; Dang S; Liu G; Li L; Huang T; Chen S; Song L
Sci Rep; 2019 Oct; 9(1):15767. PubMed ID: 31673068
[TBL] [Abstract][Full Text] [Related]
46. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.
Bourdais R; Rousseau B; Pujals A; Boussion H; Joly C; Guillemin A; Baumgaertner I; Neuzillet C; Tournigand C
Crit Rev Oncol Hematol; 2017 May; 113():242-248. PubMed ID: 28427513
[TBL] [Abstract][Full Text] [Related]
47. Interpretation of somatic POLE mutations in endometrial carcinoma.
León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
49. Mouse model and human patient data reveal critical roles for Pten and p53 in suppressing POLE mutant tumor development.
Park VS; Sun MJS; Frey WD; Williams LG; Hodel KP; Strauss JD; Wellens SJ; Jackson JG; Pursell ZF
NAR Cancer; 2022 Mar; 4(1):zcac004. PubMed ID: 35252866
[TBL] [Abstract][Full Text] [Related]
50. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance.
Bellido F; Pineda M; Aiza G; Valdés-Mas R; Navarro M; Puente DA; Pons T; González S; Iglesias S; Darder E; Piñol V; Soto JL; Valencia A; Blanco I; Urioste M; Brunet J; Lázaro C; Capellá G; Puente XS; Valle L
Genet Med; 2016 Apr; 18(4):325-32. PubMed ID: 26133394
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis.
McAlpine JN; Chiu DS; Nout RA; Church DN; Schmidt P; Lam S; Leung S; Bellone S; Wong A; Brucker SY; Lee CH; Clarke BA; Huntsman DG; Bernardini MQ; Ngeow J; Santin AD; Goodfellow P; Levine DA; Köbel M; Kommoss S; Bosse T; Gilks CB; Talhouk A
Cancer; 2021 Jul; 127(14):2409-2422. PubMed ID: 33793971
[TBL] [Abstract][Full Text] [Related]
52. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
[TBL] [Abstract][Full Text] [Related]
53. POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East.
Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Masoodi T; Siraj N; Al-Rasheed M; Kong Y; Ahmed SO; Al-Obaisi KAS; Victoria IG; Arshad M; Al-Dayel F; Abduljabbar A; Ashari LH; Al-Kuraya KS
Mol Genet Genomic Med; 2020 Aug; 8(8):e1368. PubMed ID: 32567205
[TBL] [Abstract][Full Text] [Related]
54. Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours.
Andrianova MA; Chetan GK; Sibin MK; Mckee T; Merkler D; Narasinga RK; Ribaux P; Blouin JL; Makrythanasis P; Seplyarskiy VB; Antonarakis SE; Nikolaev SI
J Pathol; 2017 Nov; 243(3):331-341. PubMed ID: 28805995
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathological characteristics and prognostic value of POLE mutations in endometrial cancer: A systematic review and meta-analysis.
He Y; Wang T; Li N; Yang B; Hu Y
Medicine (Baltimore); 2020 Feb; 99(8):e19281. PubMed ID: 32080141
[TBL] [Abstract][Full Text] [Related]
56. Novel POLE pathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures.
Castellsagué E; Li R; Aligue R; González S; Sanz J; Martin E; Velasco À; Capellá G; Stewart CJR; Vidal A; Majewski J; Rivera B; Polak P; Matias-Guiu X; Brunet J; Foulkes WD
Hum Mutat; 2019 Jan; 40(1):36-41. PubMed ID: 30362666
[TBL] [Abstract][Full Text] [Related]
57. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
[TBL] [Abstract][Full Text] [Related]
58. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer.
Esteban-Jurado C; Giménez-Zaragoza D; Muñoz J; Franch-Expósito S; Álvarez-Barona M; Ocaña T; Cuatrecasas M; Carballal S; López-Cerón M; Marti-Solano M; Díaz-Gay M; van Wezel T; Castells A; Bujanda L; Balmaña J; Gonzalo V; Llort G; Ruiz-Ponte C; Cubiella J; Balaguer F; Aligué R; Castellví-Bel S
Oncotarget; 2017 Apr; 8(16):26732-26743. PubMed ID: 28423643
[TBL] [Abstract][Full Text] [Related]
59. Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma.
Vande Perre P; Siegfried A; Corsini C; Bonnet D; Toulas C; Hamzaoui N; Selves J; Chipoulet E; Hoffmann JS; Uro-Coste E; Guimbaud R
Fam Cancer; 2019 Apr; 18(2):173-178. PubMed ID: 30368636
[TBL] [Abstract][Full Text] [Related]
60. Germline RAD54L with somatic POLE defect implicated in Hypermutation phenotype: case report.
Zohud BA; Wang M; Cai X
BMC Gastroenterol; 2020 Aug; 20(1):255. PubMed ID: 32758138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
